{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:39:24Z","timestamp":1790170764742,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11096-019-00864-w","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T08:05:47Z","timestamp":1561017947000},"page":"1056-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Estimation of apparent clearance of valproic acid in adult Saudi patients"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-8187","authenticated-orcid":false,"given":"Saeed","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Alandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"Suppl 4","key":"864_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1528-1167.2005.463007.x","volume":"46","author":"E Perucca","year":"2005","unstructured":"Perucca E. An introduction to antiepileptic drugs. Epilepsia. 2005;46(Suppl 4):31\u20137.","journal-title":"Epilepsia."},{"issue":"4","key":"864_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2710.1995.tb00651.x","volume":"20","author":"BE Gidal","year":"1995","unstructured":"Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther. 1995;20(4):215\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"864_CR3","unstructured":"Aluisio AR, Zehtabchi S. Valproate for adult migraine prophylaxis. Am Fam Physician. 2016;94(9):Online."},{"issue":"10","key":"864_CR4","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/cncr.23433","volume":"112","author":"P Shah","year":"2008","unstructured":"Shah P, Mato A, Luger SM. Valproic acid for the treatment of myeloid malignancies. Cancer. 2008;112(10):2324\u20135.","journal-title":"Cancer"},{"key":"864_CR5","unstructured":"Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician. 2000;62(6):1343\u201353, 57\u20138."},{"issue":"6","key":"864_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jphp.12209","volume":"66","author":"T Vella","year":"2014","unstructured":"Vella T, Mifsud J. Interactions between valproic acid and quetiapine\/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring. J Pharm Pharmacol. 2014;66(6):747\u201359.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"864_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","volume":"5","author":"R Gugler","year":"1980","unstructured":"Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1980;5(1):67\u201383.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"864_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","volume":"15","author":"G Zaccara","year":"1988","unstructured":"Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid\u20131988. Clin Pharmacokinet. 1988;15(6):367\u201389.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"864_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","volume":"72","author":"RL Smith","year":"2016","unstructured":"Smith RL, Haslemo T, Refsum H, Molden E. Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72(9):1099\u2013104.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"864_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","volume":"29","author":"T Correa","year":"2008","unstructured":"Correa T, Rodriguez I, Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos. 2008;29(9):511\u201320.","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"864_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"ES El Desoky","year":"2004","unstructured":"El Desoky ES, Fuseau E, El Din Amry S, Cosson V. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol. 2004;59(11):783\u201390.","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"864_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","volume":"37","author":"WW Lin","year":"2015","unstructured":"Lin WW, Jiao Z, Wang CL, Wang HY, Ma CL, Huang PF, et al. Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit. 2015;37(1):76\u201383.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"864_CR13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","volume":"37","author":"E Yukawa","year":"1997","unstructured":"Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997;37(12):1160\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"864_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","volume":"24","author":"BB Serrano","year":"1999","unstructured":"Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999;24(1):73\u201380.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"864_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00606683","volume":"13","author":"U Klotz","year":"1978","unstructured":"Klotz U, Rapp T, Muller WA. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol. 1978;13(1):55\u201360.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"864_CR16","first-page":"25","volume":"37","author":"CL DeVane","year":"2003","unstructured":"DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37(Suppl 2):25\u201342.","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"864_CR17","first-page":"1490","volume":"38","author":"RA Hamilton","year":"1981","unstructured":"Hamilton RA, Garnett WR, Kline BJ, Pellock JM. Effects of food on valproic acid absorption. Am J Hosp Pharm. 1981;38(10):1490\u20133.","journal-title":"Am J Hosp Pharm."},{"issue":"2","key":"864_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10928-006-9043-z","volume":"34","author":"M Lavielle","year":"2007","unstructured":"Lavielle M, Mentre F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn. 2007;34(2):229\u201349.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"864_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","volume":"20","author":"B Blanco-Serrano","year":"1999","unstructured":"Blanco-Serrano B, Otero MJ, Santos-Buelga D, Garcia-Sanchez MJ, Serrano J, Dominguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos. 1999;20(5):233\u201340.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"864_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","volume":"39","author":"J Methaneethorn","year":"2017","unstructured":"Methaneethorn J. Population pharmacokinetics of valproic acid in patients with Mania: implication for individualized dosing regimens. Clin Ther. 2017;39(6):1171\u201381.","journal-title":"Clin Ther"},{"issue":"10","key":"864_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1358\/mf.2007.29.10.1116313","volume":"29","author":"SM Jankovic","year":"2007","unstructured":"Jankovic SM, Milovanovic JR. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2007;29(10):673\u20139.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"11","key":"864_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.5414\/CPP48767","volume":"48","author":"SM Jankovic","year":"2010","unstructured":"Jankovic SM, Milovanovic JR, Jankovic S. Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther. 2010;48(11):767\u201375.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"864_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","volume":"65","author":"D Jiang","year":"2009","unstructured":"Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 2009;65(12):1187\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"864_CR24","doi-asserted-by":"publisher","first-page":"e0141266","DOI":"10.1371\/journal.pone.0141266","volume":"10","author":"H Nakashima","year":"2015","unstructured":"Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T, et al. Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE. 2015;10(10):e0141266.","journal-title":"PLoS ONE"},{"issue":"6","key":"864_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","volume":"27","author":"HM Park","year":"2002","unstructured":"Park HM, Kang SS, Lee YB, Shin DJ, Kim ON, Lee SB, et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002;27(6):419\u201325.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"864_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","volume":"38","author":"K Vucicevic","year":"2009","unstructured":"Vucicevic K, Miljkovic B, Pokrajac M, Prostran M, Martinovic Z, Grabnar I. The influence of drug\u2013drug interaction and patients\u2019 characteristics on valproic acid\u2019s clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci. 2009;38(5):512\u20138.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"864_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"864_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","volume":"29","author":"AK Birnbaum","year":"2007","unstructured":"Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE. Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit. 2007;29(5):571\u20135.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"864_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","volume":"40","author":"M Ibarra","year":"2013","unstructured":"Ibarra M, Vazquez M, Fagiolino P, Derendorf H. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40(4):479\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"864_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2217\/pgs.12.78","volume":"13","author":"D Chatzistefanidis","year":"2012","unstructured":"Chatzistefanidis D, Georgiou I, Kyritsis AP, Markoula S. Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics. 2012;13(9):1055\u201371.","journal-title":"Pharmacogenomics."},{"issue":"6","key":"864_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","volume":"3","author":"PC Ho","year":"2003","unstructured":"Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3(6):335\u201342.","journal-title":"Pharmacogenomics J."},{"issue":"2","key":"864_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci. 2006;94(2):261\u201371.","journal-title":"Toxicol Sci"},{"issue":"4","key":"864_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","volume":"112","author":"L Tan","year":"2010","unstructured":"Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg. 2010;112(4):320\u20133.","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"864_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"MM Zhu","year":"2017","unstructured":"Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017;62(12):1009\u201314.","journal-title":"J Hum Genet"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00864-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00864-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00864-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T23:28:51Z","timestamp":1609975731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00864-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00864-w","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}